Silvia Paola Caminiti

List of Publications by Citations

25 papers	574 citations	14 h-index	23 g-index
27 ext. papers	794 ext. citations	5.8 avg, IF	3.84 L-index

#	Paper	IF	Citations
25	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. *NeuroImage: Clinical*, **2018**, 18, 167-177	5.3	65
24	Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson]s disease. *NeuroImage: Clinical*, **2017**, 14, 734-740	5.3	54
23	Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 499-508	8.8	54
22	Altered brain metabolic connectivity at multiscale level in early Parkinson]s disease. *Scientific Reports*, **2017**, 7, 4256	4.9	40
21	Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 1311-1325	7.3	39
20	Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia. *NeuroImage: Clinical*, **2015**, 9, 484-97	5.3	37
19	The emerging role of PET imaging in dementia. *F1000Research*, **2017**, 6, 1830	3.6	36
18	Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. *Neurology*, **2018**, 90, e1029-e1037	6.5	36
17	Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. *Alzheimer's Research and Therapy*, **2019**, 11, 20	9	35
16	Evaluation of an optimized [F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. *European Journal of Neurology*, **2017**, 24, 687-e26	6	29
15	Validation of F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners. *Neuroinformatics*, **2017**, 15, 151-163	3.2	25
14	The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer]s disease. *Alzheimer's Research and Therapy*, **2020**, 12, 50	9	23
13	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson]s Disease. *Movement Disorders*, **2020**, 35, 1416-1427	7	22
12	The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. *Cortex*, **2018**, 108, 13-24	3.8	15
11	Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies. *Human Brain Mapping*, **2019**, 40, 4537-4550	5.9	14
10	Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. *Neurological Sciences*, **2019**, 40, 515-521	3.5	10
9	In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimer]s Disease. *Journal of Alzheimer's Disease*, **2020**, 75, 1003-1016	4.3	9

List of Publications

8	Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD. *Neuropsychologia*, **2019**, 133, 107174	3.2	7
7	Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2486-2499	8.8	6
6	Impaired metabolic brain networks associated with neurotransmission systems in the synuclein spectrum. *Parkinsonism and Related Disorders*, **2020**, 81, 113-122	3.6	5
5	Brain Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-(R)-PK11195 PET Study. *Journal of Alzheimerts Disease*, **2021**, 80, 433-445	4.3	4
4	PET Neuroimaging in Dementia Conditions **2021**, 211-282		2
3	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer]s disease phases. *Alzheimerts Research and Therapy*, **2021**, 13, 187	9	1
2	Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson]s Disease Patients with GBA Mutations. *Movement Disorders*, **2021**,	7	1
1	Hypoglycemia-induced brain hypometabolism captured in real time by FDG-PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1686-1687	8.8	1